Introduction
Major advances in the past 2 decades have enhanced our understanding of the complex interactions between the immune system and cancer cells and their environment. Genetic and epigenetic alterations in tumor cells result in diverse antigenic expression that can elicit an immune response, primarily mediated by T cells. Immune responses are regulated by stimulatory, costimulatory, and inhibitory (checkpoint) signals. Inhibitory signals play an important role in self-tolerance under normal conditions. In the presence of tumor cells, immune checkpoint pathways can be disrupted, resulting in tumoral immune resistance. In the past few decades, several approaches have been proposed to enhance host antitumor responses. Among the most salient strategies is the use of monoclonal antibodies against regulatory immune checkpoint molecules that inhibit T cell activation (1) . These agents up-regulate the immune function by blocking checkpoint inhibition, resulting in durable tumor responses in patients with metastatic disease that are not seen with traditional chemotherapy. Nonetheless, despite its impressive therapeutic benefits, checkpoint blockade can induce profound inflammatory and immune-related adverse events (AEs), which can be severe and limit use of checkpoint inhibition (2) .
Tumor immunity
More than a century ago, scientists proposed the existence of interactions between the immune system and tumors, which now are established as a hallmark of the physiologic host response to cancer (3) . Several decades later, experiments using carcinogen-induced and mouse models of spontaneous tumors showed that tumor cells are antigenic, and that the immune system can recognize and eradicate them (4) . These observations led to the immunosurveillance hypothesis, namely, that the immune system detects and destroys nascent transformed cells to prevent tumor development and growth (5) . Subsequent studies showed that the development of both spontaneous and carcinogen-induced tumors was comparable in immunocompetent as well as athymic (nude) mice (6) . In the 1990s, improved mouse models of immunodeficiency with pure genetic backgrounds revived the immunosurveillance theory (6) , which later was expanded to propose the concept of immunoediting, by which the immune system not only suppresses tumor growth but also shapes tumor immunogenicity (6) . Three sequential phases were proposed: "elimination," "equilibrium," and "escape" (6) .
Elimination. Both the innate and adaptive immune systems cooperate to detect and destroy transformed cells before they develop into a tumor. Immune cells recognize transformed cells and become activated via classic danger signals such as type I interferon (IFN), damage-associated molecular patterns, and stress ligands on transformed cells, including RAE-1, H60, and MICA/ B (6) . A hallmark of this immune response is the presence of tumor-infiltrating lymphocytes (TILs) within the microenvironment of the tumor. The presence of TILs has been associated with a better prognosis. Once activated, TILs, including tumor-specific CD4 and CD8 T cells, natural killer (NK) T cells, and g/d T cells, as well as M1 macrophages and dendritic cells, collaboratively eradicate transformed cells; this effect is mediated by cytotoxic molecules such as IFN, interleukin-12 (IL-12), tumor necrosis factor (TNF), NK cell receptor group 2D, TRAIL, and perforin.
Equilibrium. Some transformed cells may evade elimination. During equilibrium, the immune system is able to control tumor growth but does not completely eliminate it. Mice with induced tumors were observed on microscopy to have cancer cells at the site of injection without developing an apparent tumor for a long period of time; however, when T cells or IFNg was depleted, the tumor emerged rapidly (7) . Equilibrium is believed to be the longest immunoediting phase, lasting for decades in some cancers (6) . During this phase, the immune system also sculpts the immunogenicity of tumor cells by providing continuous selection pressure.
Escape. During the equilibrium phase, tumor cells gradually lose immunogenicity, to the point at which they escape immune recognition and destruction. Both intrinsic and extrinsic mechanisms contribute to tumor cell escape. Tumor cell intrinsic mechanisms include 1) expressing less tumor-specific antigens as well as surface major histocompatibility (MHC) class I molecules, 2) impairing the loading of peptide antigens on MHC class I molecules, 3) down-modulating expression of costimulatory factors while enhancing expression of inhibitory factors such as programmed cell death ligand (PD-L), and 4) secreting immunosuppressive mediators (8) . Along with tumor cell intrinsic mechanisms, Treg cells, myeloid-derived suppressor cells, and M2 macrophages emerge in the tumor microenvironment and suppress antitumor immunity, helping tumor cells expand and escape.
Immune checkpoint inhibitors for the treatment of cancer T cells are major players in tumoral immune responses and have been targeted in therapeutic efforts to increase antitumor immunity. One of the salient mechanisms leading to tumoral immune resistance is the upregulation of processes inhibiting the immune response. Immune checkpoints are regulatory inhibitory pathways that contribute to immune homeostasis by modulating the intensity and duration of immune responses. They are essential in preventing autoimmunity, maintaining selftolerance, and avoiding tissue damage that could result from persistent immune activation (9) . Antibodies blocking these inhibitory checkpoints enhance the immune response, with beneficial antitumoral effects (10) . On the other hand, the same enhancement of the immune response can give rise to undesirable, off-target, immunerelated, and inflammatory events.
Four checkpoint inhibitors have been approved by the US Food and Drug Administration (FDA) for the treatment of cancer: ipilimumab (a CTLA-4 inhibitor), pembrolizumab and nivolumab (anti-PD-1), and atezolizumab (anti-PD-L1). Many other agents are Signal 1 is delivered via T cell receptor (TCR) when it engages with an antigen bound to the major histocompatibility complex (MHC) molecule on the antigen-presenting cell (APC). Signal 2 is delivered via CD28 when it engages with CD80/86 on APCs. After activation, T cells express CTLA-4 on the surface that binds to CD80/86 with significantly higher affinity, blocking T cell activation. Treg cells also constitutively express CTLA-4, as an inhibitory extrinsic mechanism leading to tumor cell escape. B, Anti-CTLA-4 agents prevent CTLA-4 from binding to CD80/86, reinvigorating the inhibited T cell. They also deplete Treg cells via antibody-dependent cell-mediated cytotoxicity.
being evaluated in clinical trials. This review pertains primarily to FDA-approved inhibitors.
Anti-CTLA-4 inhibitors. Full activation of T cells requires 2 signals: 1) binding of the T cell receptor (TCR) to the antigen presented by MHC on antigenpresenting cells (APCs), and 2) costimulation by engagement of the TCR CD28 to CD80/86 on APCs. Once activated, T cells undergo robust proliferation and clonal expansion. Activated T cells then express negative immune regulators (checkpoints) on the surface to terminate activation and prevent unnecessary tissue injury. CTLA-4 is a receptor that inhibits T cell activation by blocking CD28-CD80/86 engagement via its greater affinity to CD80/86 (Figure 1) , providing a signal to APCs to reduce CD80/86 expression and to secret indoleamine dioxygenase, an immunosuppression mediator (11) . In addition, Treg cells, a CD4 T cell subset specialized in global regulation of the innate and adaptive immune systems, constitutively express CTLA-4, which is one of the suppressor mechanisms of Treg cells. Initial murine studies showed enhanced antitumor responses following CTLA-4 inhibition in both solid and hematologic tumors (12) , which was later confirmed in humans. Blocking of CTLA-4 results in persistent T cell activation (13) . Moreover, within the tumor microenvironment, this inhibition increases the ratio of Teff cells to Treg cells, depleting intratumoral Treg cells via Fc receptor-mediated, antibody-dependent cell-mediated cytotoxicity (14) .
Ipilimumab, a fully human IgG1 anti-CTLA-4 monoclonal antibody, was the first checkpoint inhibitor approved by the FDA for the treatment of advanced melanoma. Clinical trials showed impressive efficacy and survival benefits far exceeding those observed with other chemotherapeutic agents. In contrast to the immune effects of ipilimumab, abatacept, used for the treatment of rheumatoid arthritis (RA), is a soluble form of CTLA-4 that down-regulates the immune response through its affinity with CD80/86.
Anti-PD-1 inhibitors. PD-1 receptors are expressed on the surface of T cells within 24 hours after activation, disappearing once the antigen is eradicated (15) . PD-1 down-modulates TCR signaling through abrogation of phosphatidylinositol 3-kinase activity. Consequently, PD-1 alters the survival, proliferation, and functions of Teff cells (15) (Figure 2 ). When Teff cells encounter antigens continuously, such as in the setting of chronic infections or cancer, T cells lose the ability to respond to the antigen; this status is termed exhaustion, with PD-1 signaling playing a critical role (16) . Of note, PD-1 signals also promote induction of Treg cells. PD-1 has 2 ligands: PD-L1 and PD-L2. PD-L1 is widely expressed on hematopoietic and nonhematopoietic cells, including heart, endothelium, pancreatic islets, small bowel, and placenta, while PD-L2 is expressed mainly on dendritic cells and macrophages (17) . Both PD-L1 and PD-L2 (but especially PD-L1) are induced by inflammatory cytokines, including IFNs, TNF, and vascular endothelial growth factor. Thus, the induction of PD-L1 in tissue cells within an inflammatory milieu may be a protective mechanism to down-regulate Teff cell activity in tissue (17) . PD-L1 and PD-L2 are also expressed on various tumor cells, which could partly explain the ability of tumor cells to evade immunosurveillance. Initial murine studies showed that PD-1/PD-L1 blockade restored exhausted Teff cells in tumor microenvironments, leading to the clinical development of anti-PD-1 inhibitors for cancer immunotherapy.
Pembrolizumab, an engineered humanized antibody, and nivolumab, a fully human IgG4 monoclonal antibody, are anti-PD-1 inhibitors blocking the binding of PD-1 to PD-L1 (18) (19) (20) . Both agents are approved for the treatment of melanoma, non-small cell lung cancer (NSCLC), and head and neck cancer. Nivolumab is also approved for the treatment of renal cell carcinoma and Hodgkin's lymphoma. Head-to-head comparisons between anti-CTLA-4 and anti-PD-1 agents have shown the latter to be at least as efficacious and better tolerated (21, 22) .
Anti-PD-L1 inhibitors. Atezolizumab is an anti-PD-L1 engineered humanized IgG1 monoclonal antibody recently approved for the treatment of urothelial carcinoma and NSCLC. It up-regulates T cell activation by blocking the interaction between PD-1 and PD-L1 (23) . The safety profile of atezolizumab might be similar to that of anti-PD-1 agents, but it has not been evaluated in regular clinical settings.
Combination therapy. Combination immunotherapy is increasingly being proposed for the treatment of advanced cancer, not only combining immunomodulators with traditional therapy such as radiation or chemotherapy but also combining 2 or more strategies targeting the immune system (24, 25) . The FDA has approved the combination of ipilimumab and nivolumab for the treatment of metastatic melanoma. Although these combinations may improve efficacy, they result in significantly increased toxicity (21, 26) .
Treatment of immune-related AEs with checkpoint inhibitors
Therapy with checkpoint inhibitors can be hampered by a broad spectrum of inflammatory and AEs affecting many organs and systems; these AEs often are severe and occasionally are fatal (27) (28) (29) . Up to 80% of patients receiving checkpoint inhibitors can experience AEs. Most commonly, they occur within the first 3-4 months of therapy, occasionally after a single dose, but can also occur at a later stage. Some AEs, such as rash and colitis, are recognized promptly, but others such as endocrinopathies or pneumonitis can be more insidious. Constitutional symptoms, especially fatigue, are common. Although the majority of the AEs are transient, some, especially endocrinopathies and neurologic syndromes, can have long-lasting effects and sequelae (30) .
Clinical manifestations of AEs. Most AEs can be associated with all checkpoint inhibitors, but some occur more frequently with a given agent. In general, anti-PD-1 agents seem to be better tolerated; they can trigger AEs similar to those associated with ipilimumab, including dermatitis and hepatotoxicity, with some variations (29) . The toxicity of newer anti-PD-L1 agents is not as well described (23) . Combination therapy, compared to monotherapy, increases the frequency of AEs (21) . Table 1 shows the frequency of selected AEs for each class of therapy as observed in clinical trials and reported in systematic reviews.
Dermatitis. Skin manifestations are the most common AEs seen with all checkpoint inhibitors. The majority of patients have self-limited disease, with rash and/or pruritus. Vitiligo is also common. Rarely, patients can develop severe disease, with toxic epidermal necrolysis. Psoriasis has also been reported.
Enterocolitis. Diarrhea occurs in up to 30% of patients receiving ipilimumab and less frequently in patients receiving anti-PD-1 therapy. The incidence and severity of enterocolitis increase in patients receiving combination therapy. Colonoscopic and histologic findings resemble those observed in idiopathic inflammatory bowel (Figure 3) , with inflammatory infiltrates including neutrophils, and primarily CD4 lymphocytes. Severe colitis can lead to bowel perforation. Anecdotally, some patients who received ipilimumab and developed colitis were subsequently treated with anti-PD-1 therapy without recurrence of colitis. Endocrinopathies. Several endocrinopathies have been reported in patients receiving checkpoint blockade. Thyroiditis is the most commonly reported AE, most often presenting as hypothyroidism but occasionally as hyperthyroidism, and it is more frequently observed with anti-PD-1 therapy than with ipilimumab. Testing of thyroid function is required before starting treatment. Hypophysitis has been observed primarily in patients receiving ipilimumab ( Figure 4 ) and can occur in up to 5% of patients, more commonly in men than in women. It is characterized by lymphocytic infiltrates resembling idiopathic autoimmune hypophysitis. Symptoms include nausea, headache, and fatigue. Patients should be evaluated for deficiencies of hormones in the anterior pituitary gland, most commonly hypothyroidism. Imaging of the brain shows pituitary enlargement. Other endocrinopathies include hypogonadism, primary adrenal insufficiency, pancreatitis, and type 1 diabetes mellitus. Although inflammation can be treated, many patients develop long-term sequelae, especially hypothyroidism and adrenal insufficiency, and require longterm hormone replacement therapy.
Autoimmune hepatitis. Elevated levels of hepatic enzymes can be observed in ;5% of patients, more frequently in those receiving combination therapy. Regular monitoring of liver function is advisable. An elevation in transaminase levels is the first sign of liver inflammation, which can be followed by abdominal pain, nausea, and jaundice.
Pneumonitis. Pneumonitis has been observed more frequently in patients treated with nivolumab compared with other agents. However, this is primarily because nivolumab is approved for the treatment of lung cancer, and preexisting pulmonary disease is a risk factor for pneumonitis. Pneumonitis has also been reported in patients receiving ipilimumab. Symptoms include dry cough and shortness of breath. Physical examination can reveal fine crackles. Computed tomography, spirometry, and carbon monoxide diffusing capacity measurements are indicated if pneumonitis is suspected. Imaging shows ground-glass lesions or small nodular infiltrates.
Arthritis. Arthralgia has been observed in ;15% of patients receiving checkpoint blockade. However, the incidence of inflammatory arthritis has not been systematically reported. A recent study of patients evaluated in the Johns Hopkins rheumatology clinics identified 9 patients who received ipilimumab and/or nivolumab in whom inflammatory arthritis developed (31) . The clinical presentations of these patients were variable, involving both large and small joints. Two patients presented with features of reactive arthritis, including urethritis and conjunctivitis. Six other patients developed RA-like symmetric polyarthritis. Four of the 9 patients also developed colitis. No patients were positive for rheumatoid factor (RF) or anti-cyclic citrullinated (anti-CCP) antibodies, and 3 were positive for antinuclear antibodies (ANAs). One of the patients had erosive disease. Most of the patients received glucocorticoids but generally required higher doses than those used in clinical practice to treat inflammatory polyarthritis. A few patients required methotrexate and/or anti-TNF therapy. Some patients had persistent disease for months after discontinuation of checkpoint therapy.
Although arthritis is a very common manifestation of autoimmune disease, it has not been frequently reported as an AE in clinical trials of checkpoint inhibitors. At face value, it appears likely that the prevalence of arthritis might be underrepresented, because most oncology clinical trial publications report primarily grade 3 or higher adverse events, and arthritis may not be considered as severe as other AEs (32) . Nevertheless, this observation is intriguing and may help elucidate further immune mechanisms related to the development of arthritis within the spectrum of autoimmune disease.
We describe below 2 different patients seen at our institution who developed arthritis after checkpoint inhibition, helping to illustrate the variation in jointrelated manifestations. Patient 1, a 46-year-old man with a history of metastatic duodenal cancer, developed oligoarthritis 9 weeks after initiation of a phase I trial of anti-PD-1 antibody in combination with an anti-T cell immunoglobulin and mucin domain-containing protein antibody. The patient had moderate-to-large effusions in both knees and the left ankle. ANAs were weakly positive (1:80), and RF and anti-CCP antibodies were negative. Arthrocentesis with intraarticular corticosteroid injections was performed. The synovial fluid was inflammatory (cell count 4,000-10,000/ml) with no evidence of crystals, and the results of a culture were negative. The patient did not improve with the steroid injections, and he was treated with oral prednisone, 40 mg orally daily, with a good response and subsequent dose tapering.
Patient 2, a 71-year-old woman with NSCLC and no prior history of joint disease, developed polyarthritis in her hands after receiving 3 doses of nivolumab. Her laboratory tests showed RF positivity (38.5 IU [normal ,15.9]) and negativity for anti-CCP antibodies and ANAs. Nivolumab was discontinued, and the patient was treated with oral prednisone. Her synovitis markedly improved, although mild joint tenderness and morning stiffness persisted. After a few months, the patient had progression of her tumor and was rechallenged with nivolumab; she rapidly (within a few weeks) experienced a polyarthritis flare, and nivolumab was again discontinued. Little is known about the immune pathophysiology of arthritis as an AE, but we hypothesize that these 2 cases perhaps reflect different aspects of an upregulated immune response. The first case might represent up-regulation of the immune system, resulting in a non-disease-specific arthritis, perhaps idiosyncratic. The second case could represent the onset of RA in a genetically or environmentally predisposed individual.
Sicca syndrome. The report from Johns Hopkins also described 4 patients who developed sicca syndrome while receiving checkpoint inhibition therapy (31) . Three of the patients had positive ANAs, and 1 patient had low-titer SSB antibodies. Other reported AEs. In addition to the more common AEs summarized above, various other inflammatory or autoimmune events or syndromes have been reported. We recently conducted a systematic review of case reports of AEs in patients receiving checkpoint blockade, the majority of whom were treated with ipilimumab. These AEs included lupus-like or acute/ granulomatous interstitial nephritis, acute tubular necrosis with renal failure, myositis, polymyalgia rheumatica/ giant cell arteritis, sarcoidosis, uveitis, episcleritis, celiac disease, myocarditis, cytopenias, various neurologic syndromes such as myasthenia and transverse myelitis, and other rare disorders (33) .
Pathophysiology of AEs. Although the cellular and molecular mechanisms of AEs induced by checkpoint blockade are not fully elucidated, accumulating evidence provides insights regarding potential mechanisms. Anti-CTLA-4 and anti-PD-1 agents share similarities but also have differences in their effects, which could conceivably explain some of the variation in the frequency and phenotypes of AEs caused by each class of therapy.
Generally, checkpoint blockade results in enhanced Th1 and Th17 cell responses, with enhanced production of cytokines such as IL-6 and IL-17 (34, 35) . In addition, murine and human studies of checkpoint inhibition show impaired function and survival of Treg cells. Treg cells express CTLA-4 continuously, terminating T cell activation by inhibiting CD28-CD80/86 engagement. Blocking of CTLA-4 impairs Treg cell survival and functions. An altered Treg cell/Th17 cell axis is critical in the development of many autoimmune diseases, including IBD, psoriatic arthritis (PsA), and many others (36) . Recent investigations have also implicated Th17 cells as key mediators of checkpoint blockadeinduced colitis. Mice in which CTLA-4 on Treg cells is genetically deleted have dysfunctional Treg cells and T cell-mediated autoimmune diseases (37) . The serum level of IL-17 (a potent inflammatory cytokine produced by Th17 cells) is increased in patients with ipilimumabinduced colitis (38) compared to patients without immune-related AEs. Moreover, a high baseline serum IL-17 level is associated with colitis after ipilimumab therapy (39) .
Altered T cell-B cell interactions can result in pathogenic autoantibody production and appear to contribute to the development of AEs. Repetitive injections of anti-CTLA-4 into normal mouse strains induced hypophysitis with development of serum antipituitary antibodies (40) . Several case reports of patients with ipilimumab-induced AEs described autoantibodies against specific tissues affected by AEs (41), including perinuclear antineutrophil cytoplasmic antibodies and anti-OmpC antibodies in colitis (42) , anti-double-stranded DNA antibodies in lupus-like nephritis (43) , anti-factor VIII antibodies in hemophilia (44) , antipituitary antibodies in hypophysitis (40) , and anti-thyroid peroxidase and antithyroglobulin antibodies in thyroiditis (45) .
The mechanisms underlying AEs occurring with PD-1/PD-L1 inhibition are also poorly understood. As observed with ipilimumab, altered Treg cells and heightened humoral immunity appear to play key roles. The suppressor function of human Treg cells is decreased in vitro in the presence of anti-PD-1 antibody (46) . Murine studies show that PD-1 signaling enhances Treg cell expression of FoxP3 (a key transcription factor governing the function and survival of Treg cells), and that blocking PD-1 impairs function and survival (47, 48) . The cardiac biopsy of a patient receiving pembrolizumab who developed acute congestive heart failure revealed prominent CD8 T cell infiltrates with apoptotic Treg cells (49) . Some patients who developed inflammatory arthritis with nivolumab had presentations similar to those of patients with spondyloarthritides, diseases with Th17 cell up-regulation (31) . PD-1 inhibition also heightens humoral immunity with production of pathogenic autoantibodies. Depending on their various genetic backgrounds, PD-1-knockout mice develop various autoimmune phenotypes mediated by pathogenic autoantibodies (50) (51) (52) (53) . This has also been reported in humans treated with nivolumab who developed thrombocytopenia, diabetes, or thyroiditis, associated with tissue-specific autoantibodies (54) .
Although CTLA-4 inhibition and PD-1 inhibition share clear similarities in terms of up-regulation of the immune system, leading to abnormal Treg cell function and humoral immunity, the differences in the frequency and phenotypes of AEs are not well understood. Furthermore, many patients do not develop AEs despite continued use of an agent, and some who develop AEs with ipilimumab do not develop the same events with subsequent PD-1 inhibition. Pathogenic autoantibody production might be more critical in AEs induced by anti-PD-1, while dysfunctional Treg cell2 and Th17 cell-mediated autoimmunity may be more relevant in anti-CTLA-4 toxicity (41). Several areas of future research might help elucidate the observed differences. The genetic background of the host must play a role, because some individuals are more predisposed to autoimmunity than are others.
The microbiome may influence the development of AEs. A recent study showed that patients receiving ipilimumab had varying intestinal microbiota according to whether they developed subsequent immune-mediated colitis, and that increased representation of Bacteroides phylum was associated with lower odds of developing colitis (55) . Because tumor cells are the antigenic source, the relationship between crossed immunity between the primary tumor and target tissues of AEs may be crucial. A recently published article described 2 patients with metastatic melanoma who developed lethal myocarditis after receiving combination therapy with ipilimumab and nivolumab (56) . Comprehensive genomic analysis of tumor samples obtained before and after checkpoint inhibitor treatment and skeletal and cardiac muscle obtained postmortem was performed; TCR analysis suggested that T cells may target an antigen shared by the tumor, skeletal muscle, and the heart. Patients receiving ipilimumab primarily have melanoma, while PD-1 inhibition has been used for the treatment of several other cancers. It is conceivable that different tumors will have variation in antigenic expression and load, which could result in differential tissue targets and AEs.
Finally, there is an ongoing debate as to whether AEs are associated with better tumor responses in patients undergoing checkpoint inhibition. Interestingly, Th17 cells, presumptively one of the key players in the development of AEs, can have different effects on tumor immunity. In animal models, Th17 cells are protumerogenic in cancers in which chronic inflammation might be a factor, including colon, pancreatic, and lung cancers. Conversely, Th17 cells directly eradicate melanoma tumor cells in mice (57, 58) . Thus, depending on the origin of the primary tumor, AEs might be associated with either positive or negative tumor responses to checkpoint inhibition.
Management of AEs. The clinical treatment of patients receiving checkpoint blockade and developing an AE requires a multidisciplinary patient-centered approach (27, 59 ). Champiat et al proposed a useful clinical framework for the management of AEs, including prevention, anticipation, detection, treatment, and monitoring (60) . A modified summary of this approach is shown in Table 2 . Risk factors for autoimmunity need to be carefully evaluated before starting treatment, to ensure personalized monitoring and prompt recognition of AEs. The diagnosis of AEs is primarily clinical. Many of the initial symptoms, such as fatigue, may be nonspecific. A patient with rash Be familiar with possible AEs involving various systems and organs When an AE occurs, consider differential diagnoses such as immune-related AEs disease progression, concomitant comorbidities, AEs caused by other drugs Perform organ/system-specific testing, including autoantibodies and imaging, as clinically indicated Inflammatory biomarkers can be useful in the diagnosis if levels are very high Consider subspecialty referral
Treatment
Glucocorticoids are usually indicated as initial therapy; consider high-dose IV pulses for severe AEs Consider hospitalization If response is inadequate, consider other immunosuppressants, ideally those that would be used in a similar noninduced autoimmune syndrome (e.g., TNF inhibitors for colitis) Consider antibiotic prophylaxis to prevent opportunistic infections (e.g., trimethoprim/ sulfamethoxazole) Glucocorticoids should be slowly tapered Discontinuation of immunotherapy Permanent for severe or persistent AEs Temporary if event is mild (e.g., rash) and can be managed with low-dose glucocorticoids Consider an alternative checkpoint inhibitor with a different mechanism of action Monitor for long-term sequelae (e.g., endocrinopathies, persistent autoimmune features) * AEs 5 adverse events; HBV 5 hepatitis B virus; HCV 5 hepatitis C virus; TB 5 tuberculosis; ANAs 5 antinuclear antibodies; CT 5 computed tomography; IV 5 intravenous; TNF 5 tumor necrosis factor.
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SUAREZ-ALMAZOR ET AL may have dermatitis arising from concomitant use of other medications; colitis or pneumonitis can be secondary to an infection. According to our experience, inflammatory markers such as C-reactive protein are good biomarkers to ascertain and to use in monitoring patients with AEs. The levels of inflammatory markers are usually highly elevated and decrease promptly with therapy. While tissuespecific autoantibodies underlie certain AEs in some patients, the majority of patients do not present with more generic autoantibodies, such as ANAs (29) .
Once an AE is identified, the goal of treatment is to avoid deleterious events and sequelae, with as little compromise of the patient's immune function as possible, to ensure that the antitumor effects of the checkpoint therapy can be maximized. Unfortunately, there is scant information as to whether some approaches may blunt tumor immunity more than others. It is unclear whether use of high-dose immunosuppressant therapies such as glucocorticoids is more appropriate than a more targeted approach, e.g., anticytokine agents such as TNF inhibitors. Most patients with AEs are initially treated with glucocorticoids and supportive therapy. The initial dose will depend on how severe and life-threatening the patient's manifestations are. Mild dermatitis can be treated with topical glucocorticoids, while severe colitis will require high-dose glucocorticoids and possibly TNF inhibitors. The potential influence of TNF inhibitors on tumor progression remains questionable, but so far, the available data suggest no risk of tumor development (61) or cancer progression, recurrence, or survival (62, 63) .
The FDA has developed a Risk Evaluation and Mitigation Strategy for severe immune-mediated AEs related to ipilimumab, on the basis of the Common Terminology Criteria for Adverse Events grading system (64) . Although this guide applies primarily to anti-CTLA-4 agents, it can be applied to AEs arising from anti-PD-1 therapy. For AEs that are potentially lifethreatening or can result in sequelae, discontinuation of treatment is recommended, with initiation of oral prednisone at 1 mg/kg/day, and possible hospitalization. For more serious events, the recommendations are to administer intravenous methylprednisolone at 2 mg/kg/day. If necessary, treatment with infliximab 5 mg/kg can be administered and repeated 2 weeks later.
For non-life-threatening rheumatologic events such as arthritis, there are no clear guidelines; our own unpublished research suggests that most patients respond well to an initial dose of 20-30 mg of prednisone, which can be tapered if checkpoint blockade is discontinued. Occasionally, disease-modifying antirheumatic drugs, including biologic therapy, might be necessary to allow quicker tapering of glucocorticoids. Endocrinopathies are treated with hormone replacement therapy. The use of higher-dose glucocorticoids for endocrinopathies alone, with no other AEs, is not universally recommended.
Most patients presenting with severe AEs are not rechallenged with the same therapy after toxicity has resolved. However, in some patients, treatment with a different checkpoint inhibitor (i.e., anti-PD-1 after the occurrence of ipilimumab-related toxicity) may not result in repeated or new AEs.
Use of checkpoint inhibitors in patients with cancer and preexisting autoimmune disease
While the underlying mechanisms involved in the development of AEs are not completely understood, the nonspecific up-regulation of T cell activation resulting from checkpoint inhibition could conceivably result in exacerbation of inflammation and autoimmunity in patients with preexisting autoimmune disease (65) . An increasing body of evidence supports the role of immune checkpoint regulation, involving both CTLA-4 and PD-1 pathways, in the pathogenesis of inflammatory and autoimmune disorders (66, 67) . In fact, abatacept, a soluble form of CTLA-4, with effects opposed to those of ipilimumab, is approved for the treatment of RA. Mice lacking CTLA-4 die of massive lymphoproliferation and inflammation. In addition, specific polymorphisms in mice have been linked to regulatory aberrations. In humans, certain CTLA-4 alleles are associated with various autoimmune diseases, including thyroiditis and neurologic disorders, IBD, and (interestingly) RA, ankylosing spondylitis (AS), and systemic lupus erythematosus (SLE) (66, (68) (69) (70) (71) . However, the functional consequences of the identified polymorphisms in these patient populations are not fully elucidated but could play a role in patients with concomitant cancer who are undergoing checkpoint inhibition.
Similar associations have been observed between specific PD-1 polymorphisms and various autoimmune diseases, including type 1 diabetes mellitus, RA, SLE, and AS (72) (73) (74) . How these genetic variations may change PD-1 pathways is still unclear; some of the associated polymorphisms are not located in coding regions. However, it is possible that certain alleles may be more successful than others in regulating self-tolerance and activation of autoreactive immune cells. These genetic variations could play a role in the development of AEs and potential exacerbation of disease activity in patients with underlying autoimmunity.
There have been sporadic case reports of patients with cancer (predominantly melanoma) and preexisting autoimmune disease who have been treated clinically practice with immune checkpoint inhibitors. Case reports have included patients with RA (75), Sj€ ogren's syndrome (76) , ulcerative colitis (77-79), Behçet's disease (79) , sarcoidosis (80, 81) , psoriasis (82) (83) (84) (85) , Churg-Strauss vasculitis (86) , multiple sclerosis (75, 87) , myasthenia gravis (88), idiopathic thrombocytopenic purpura (89), or autoimmune thyroiditis (83, (90) (91) (92) .
A recent multicenter retrospective case series reported 30 patients with melanoma and prior autoimmune disease who received ipilimumab, including patients with RA, SLE, psoriasis and/or PsA, reactive arthritis, IBD, rheumatic fever, celiac disease, sarcoidosis, autoimmune thyroiditis, multiple sclerosis, or transverse myelitis (93) . The outcomes varied, ranging from no toxicity (35.3% of patients) to exacerbation of the preexisting autoimmune disease (25.5% of patients) with life-threatening intestinal perforation in a patient with ulcerative colitis (77), or de novo AEs (29.4% of patients), which were fatal in a patient with psoriasis who developed grade 5 colitis (93); toxic epidermal necrolysis was reported in another patient with ulcerative colitis (78) . Approximately 10% of patients had both disease exacerbation and de novo events. More than one-third of patients who had preexisting active autoimmune disease at the start of treatment did not develop any AEs. De novo AEs involved mainly the skin, the gastrointestinal tract, and the endocrine system. There were 2 treatment-related deaths (78, 93) , but most AEs were controlled with glucocorticoids and few required treatment with disease-modifying antirheumatic drugs (77, 78) or infliximab (77, 78, 93) . In more than half of the cases, AEs did not require discontinuation of treatment.
In a study of 8 patients with melanoma and preexisting RA who received ipilimumab, 6 patients had a disease flare (that was mild in 4 of these patients) requiring only nonsteroidal antiinflammatory drugs. The other 2 patients required treatment with corticosteroids (94) . Although discontinuation of treatment was required in several of these patients, it was mostly because of other more severe AEs such as colitis.
The safety of pembrolizumab and nivolumab was evaluated in 119 patients with advanced melanoma who either had a preexisting autoimmune disease or had experienced severe AEs with ipilimumab therapy (95) . Fifty-two patients had preexisting RA, SLE, scleroderma, psoriasis and/or PsA, Sj€ ogren's syndrome, IBDs, celiac disease, sarcoidosis, polymyalgia rheumatica, or other autoimmune diseases. Exacerbation of the underlying autoimmune disease was reported in 38% of the patients (mainly those with active disease) when PD-1 inhibition was initiated; 29% of the patients reported other AEs. One-third of the patients did not report exacerbations or AEs, and there were no treatment-related deaths.
Because of the limited data on the safety of checkpoint inhibition in patients with cancer and preexisting autoimmune diseases, there are no clear recommendations. Further studies are required to help identify patients with autoimmune disease who are at risk of developing serious AEs or disease exacerbation. In the meantime, patients and providers need to carefully balance the potential benefits and risks of immunotherapy, recognizing the uncertainty surrounding the potential for AEs with respect to the benefits of cancer therapy.
Conclusions
Immune checkpoint inhibitors have revolutionized the treatment of cancer. Despite their benefits, they can cause severe AEs that limit their full therapeutic benefits and result in considerable morbidity and mortality. There is no clear evidence regarding whether aggressive treatment of AEs may impair the benefits of immunotherapy. Additional studies are needed to determine how to adequately control and manage AEs without a detrimental effect on tumor immunity. Because of concerns of enhanced inflammation and autoimmunity, patients with cancer and prior autoimmune disorders have typically been excluded from receiving checkpoint inhibition therapy. However, until more precise estimates of the potential harms are available, careful consideration of the risks and benefits and individual preferences need to be considered when making decisions regarding therapy for patients with cancer and autoimmune disease.
